<abstract xmlns="http://www.w3.org/1999/xhtml">Adenosine is an endogenous compound with cardioprotective properties that acts via A1, A2A, A2B and A3 plasma membrane receptors. Over the last several decades, the mechanisms underlying adenosine’s protective effects in the ischemic myocardium were investigated. They are the basis for ischemic preconditioning and postconditioning procedures that protect the heart from ischemia/reperfusion injury. The promising results of animal model studies have encouraged a large group of researchers to conduct clinical trials assessing the benefits of adenosine as an adjunct to reperfusion therapy in myocardial infarction. This review describes the mechanisms behind the cardioprotective effect of adenosine and presents current reports on its clinical utility in the treatment of myocardial infarction.</abstract>

Adenosine is an endogenous compound with cardioprotective properties that acts via A1, A2A, A2B and A3 plasma membrane receptors. Over the last several decades, the mechanisms underlying adenosine’s protective effects in the ischemic myocardium were investigated. They are the basis for ischemic preconditioning and postconditioning procedures that protect the heart from ischemia/reperfusion injury. The promising results of animal model studies have encouraged a large group of researchers to conduct clinical trials assessing the benefits of adenosine as an adjunct to reperfusion therapy in myocardial infarction. This review describes the mechanisms behind the cardioprotective effect of adenosine and presents current reports on its clinical utility in the treatment of myocardial infarction.

Adenosine receptors as therapeutic targets for the treatment of myocardial infarction and its complications. Part I. Myocardial infarction

Pomeranian Medical University in Szczecin

Department of Biochemistry and Medical Chemistry

Pomeranian Journal of Life Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Adenosine is an endogenous compound with cardioprotective properties that acts via A1, A2A, A2B and A3 plasma membrane receptors. Over the last several...

Adenosine receptors as therapeutic targets for the treatment of myocardial infarction and its complications. Part I. Myocardial infarction

Publié en ligne: 24 sept. 2019

Pages: 19 - 25

DOI: https://doi.org/10.21164/pomjlifesci.606

Mots clés
cardioprotection, ischemia-reperfusion injury, reperfusion, adenosine, adenosine receptors, myocardial infarction

© 2020 Kamila Puchałowicz et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Adenosine receptors as therapeutic targets for the treatment of myocardial infarction and its complications. Part I. Myocardial infarction

Publié en ligne: 24 sept. 2019

Pages: 19 - 25

DOI: https://doi.org/10.21164/pomjlifesci.606

Mots cléscardioprotection, ischemia-reperfusion injury, reperfusion, adenosine, adenosine receptors, myocardial infarction

© 2020 Kamila Puchałowicz et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
cardioprotection, ischemia-reperfusion injury, reperfusion, adenosine, adenosine receptors, myocardial infarction